Eisai Co Ltd - Company Profile
Powered by 
All the data and insights you need on Eisai Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Eisai Co Ltd Strategy Report
- Understand Eisai Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Eisai Catalyst Calendar
Proactively evaluate Eisai Co Ltd’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Eisai Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 01 Oct 2019 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 29 Sep 2019 | Phase I Trial Results | Eisai Co Ltd | 4523 | E-7389LF | Oncology | Adenoid Cystic Carcinoma (ACC); Breast Cancer; Esophageal Cancer; Gastric Cancer; Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer); Small-Cell Lung Cancer; Solid Tumor | Company Press Release |
| 01 Sep 2019 | Phase 0 Trial Completion | City of Hope; Eisai Co Ltd; National Cancer Institute US | 4523 | eribulin mesylate | Oncology | Brain Tumor; Malignant Neoplasms; Metastatic Brain Tumor | Clinical Trial Registry |
| 26 Aug 2019 | Phase I Trial Completion | Eisai Co Ltd; Labcorp Drug Development | 4523 | irsenontrine maleate | Central Nervous System | Lewy Body Dementia | Clinical Trial Registry |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer